Tumour growth rate as a tool for response evaluation during PD-1 treatment for non-small cell lung cancer: a retrospective analysis

BACKGROUND: Immune checkpoint inhibitors have emerged as a standard of care treatment for non-small cell lung cancer (NSCLC). To get insight into variations in tumour growth kinetics and their potential predictive values for outcome, we evaluated tumour growth rate (TGR) in patients receiving progra...

Descripción completa

Detalles Bibliográficos
Autores principales: ten Berge, Deirdre M.H.J., Hurkmans, Daniel P., den Besten, Ilse, Kloover, Jeroen S., Mathijssen, Ron H.J., Debets, Reno, Smit, Egbert F., Aerts, Joachim G.J.V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Respiratory Society 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6911925/
https://www.ncbi.nlm.nih.gov/pubmed/31857994
http://dx.doi.org/10.1183/23120541.00179-2019

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6911925/
https://www.ncbi.nlm.nih.gov/pubmed/31857994
http://dx.doi.org/10.1183/23120541.00179-2019

Ejemplares similares